P1–351: A novel BACE inhibitor (PF‐05297909): A two‐part adaptive design to evaluate safety, pharmacokinetics and pharmacodynamics for modifying beta‐amyloid in a first‐in‐human studyJ. Simon Bell, Timothy Nicholas, Yasong Lu et al.|Alzheimer s & Dementia|2013Cited by 10
P1–386: Cross‐species analysis of cerebrospinal fluid (CSF) beta‐amyloid reductions by the BACE1 inhibitor PF‐05297909 indicates species differences in PK/PD relationships: Relevance to clinical translationÉva Hajós‐Korcsok, David Riddell, Charles E. Nolan et al.|Alzheimer s & Dementia|2013Cited by 0